Author Correction: Monocytes to Apolipoprotein A1 ratio is associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus

The original version of this Article contained an error in Figures 1, 2, 3, 4, 5, and 6 where the initial statistical pictures were uploaded instead of the modified Figures. The original Figures 1 , 2 , 3 , 4 , 5 , and 6 and accompanying legends appear below. Fig. 1 The flowchart illustrates the process of study population enrollment. Full size image Fig. 2 MASLD prevalence ( A ) and metabolic dysfunctions distribution ( B ) based on MAR quartile. MAR Monocytes to Apolipoprotein A1 ratio, MASLD Metabolic dysfunction-associated fatty liver disease. Full size image Fig. 3 Correlation of MAR with CT L−S and NFS. ( A ) the negative association between MAR and CT L−S ( r = − 0.369, P < 0.001). ( B ) the positive association between MAR and NFS ( r = 0.158, P < 0.001). NFS Nonalcoholic fatty liver disease fibrosis score, MAR Monocytes to Apolipoprotein A1 ratio. Full size image Fig. 4 The independent correlation of MAR with MASLD in different Models. Model 1: adjustment for age, gender, diabetic duration, and drinking. Model 2: further adjustment for waist circumference, body mass index, systolic blood pressure, diastolic blood pressure, hemoglobin A1c, triglycerides, high-density lipoprotein, homeostasis model assessment of insulin resistance, and uric acid based on Model 1. Model 3: additional adjustment for alanine aminotransferase and aspartate aminotransferase, as well as the usage of hypoglycemic agents like metformin, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists based on Model 2. MASLD Metabolic dysfunction-associated fatty liver disease, MAR Monocytes to Apolipoprotein A1 ratio. Full size image Fig. 5 Restricted cubic spines analysis of the association between MAR and MASLD after accounting for full adjustments in Model 3. MASLD Metabolic dysfunction-associated fatty liver disease, MAR Monocytes to Apolipoprotein A1 ratio. Full size image Fig. 6 ROC analysis for comparing MASLD identifying value between MAR and MHR. MASLD Metabolic dysfunction-associated fatty liver disease, MAR Monocytes to Apolipoprotein A1 ratio, MHR Monocytes to high-density lipoprotein, BMI Body mass index, WC Waist circumference, SBP Systolic blood pressure, DBP Diastolic blood pressure, HbA1c Glycated hemoglobin, TG Triglyceride, TC Total cholesterol, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol, APOA1 Apolipoprotein A1, UA Uric acid, ALT Alanine aminotransferase, AST Aspartate aminotransferase. HOMR-IR Homeostasis model assessment insulin resistance, MAR Monocyte to APOA1 ratio, MHR Monocyte to HDL-c ratio, MASLD Metabolic dysfunction-associated fatty liver disease. Full size image